What we know today — and what’s worth doing properly
Red light has shown up almost everywhere in recent years: skincare, recovery, sports. It’s natural that sooner or later, questions about vision and eye health also come into focus. The topic is both exciting and delicate: the eye is one of our most sensitive organs, yet it is also an extremely energy-demanding system. That’s why it’s not surprising that researchers have turned their attention to the relationship between red light and the eye. In the scientific literature, this area is most often discussed not as “red light therapy,” but under the term photobiomodulation (PBM). This is more than a terminology difference. Ophthalmic PBM follows a very different logic than cosmetic or wellness-focused red light devices. Here, it’s not about general “illumination,” but a defined wavelength, a precise dose, and targeted application. Research is rooted in the observation that certain red-light wavelengths can influence mitochondrial function at the cellular level. From this perspective, the retina is particularly interesting: it’s an extremely energy-hungry tissue whose function is closely tied to ATP production, oxidative stress levels, and inflammatory processes. It’s no accident that PBM first emerged as a serious research direction in relation to retina-centered conditions. The strongest evidence so far comes from dry age-related macular degeneration (AMD). Several clinical studies and longer follow-up programs suggest that, when applied under the right conditions, PBM may improve contrast sensitivity and color vision, and in some cases may slow disease progression. This is especially notable given that treatment options for dry AMD are currently quite limited. More recently, another direction has gained attention: supporting so-called “aging vision.” Small human studies suggest that short, typically morning exposure to 670 nm red light may produce temporary improvements in contrast and color perception in older adults. These findings are highly intriguing, but it’s important to emphasize that they are research observations studied under narrow conditions—not general treatment recommendations. PBM has also appeared in discussions around dry eye syndrome, recurrent eyelid cysts (chalazion), and even slowing myopia progression, particularly in children. These areas are promising, but they currently rely on diverse protocols, different devices, and relatively small sample sizes—so we cannot speak of clinical consensus yet. Alongside the excitement, there is one point on which experts are almost universally aligned: safety is critical. The eye is not skin. The retina is part of the nervous system, and what skin tolerates well may already be too much for the eye. Several experts—including Dr. Allen—emphasize that the vast majority of red light panels and masks on the market were not designed for ophthalmic use, and they often explicitly warn against shining light directly into the eyes. At the same time, the most recent experiences and cautious recommendations point toward a narrow but promising use-case where reports describe clearly positive outcomes—without taking unnecessary risks.
At-home use: what currently seems like the best direction?
(Not medical advice, but a framework based on research experience.) For eyes, only the red range is suggested — near-infrared (NIR) light should be switched off on devices. Exposure should be short: 2–3 minutes, no more, with closed eyelids. Experience suggests that morning use fits best with the eye’s natural metabolism. The goal is not a strong light, but low-intensity, controlled stimulation. If you have an existing eye condition, any such approach should only be considered in consultation with a qualified professional. With this restrained and precise approach, real and measurable improvements in certain visual functions may be possible—while avoiding risks that come from overdoing it. A video analysis attached to the article summarizes the topic in an accessible yet professionally responsible way and provides additional context for interpreting the research findings.
The bigger picture
Red-light-based photobiomodulation is not a passing trend in ophthalmology, but a real and actively researched direction—especially in relation to retinal function. The biological mechanisms are understandable and early results are encouraging, but the field is still evolving. The best strategy at present is not “more light,” but more precise use: short duration, the right wavelength, and deliberate application. With the eye, perhaps more than anywhere else, enthusiasm must always be paired with professional restraint. This article is for educational purposes. The research findings presented do not constitute medical advice and do not replace an eye examination or treatment.
Sources used
Allen, A. (2024). Red light therapy for the eyes: Benefits, research, and safety
[Video]. YouTube.
https://www.youtube.com
(Safety-focused summary created by an optometrist)
Gkotsi, D., Begum, R., Salt, T. E., Lascaratos, G., Hogg, C., Chau, K. Y., & Jeffery, G.
(2014). Recharging mitochondrial batteries in old eyes: Near infra-red light improves
visual acuity in aged mice. Investigative Ophthalmology & Visual Science, 55(8),
5354–5362.
https://doi.org/10.1167/iovs.14-14807
Ivandic, B. T., & Ivandic, T. (2019). Low-level laser therapy improves vision in patients
with age-related macular degeneration. Photomedicine and Laser Surgery, 36(6),
1–7.
https://www.liebertpub.com/doi/10.1089/pho.2018.4604
EyeWiki. (2024). Photobiomodulation in retina diseases. American Academy of
Ophthalmology.
https://eyewiki.org/Photobiomodulation_in_Retina_Diseases
Frontiers in Ophthalmology. (2024). Photobiomodulation in ophthalmology: Current
and future perspectives.
https://www.frontiersin.org/articles/10.3389/fopht.2024.XXXXX
(Comprehensive review of mechanisms and clinical directions)
Retinal Physician. (2025). The emerging role of photobiomodulation in retinal
disease.
https://www.retinalphysician.com/issues/2025
(Professional context and clinical perspective)
ClinicalTrials.gov. (2024). Photobiomodulation in dry age-related macular
degeneration (NCT06046118).
https://clinicaltrials.gov/study/NCT06046118
